Figure 4.

COVID-19 vaccination induces expansion of SARS-CoV-2-specific tetramer⁺ T cell responses

(A) FACS plots of TAME-enriched CD4⁺ and CD8⁺ tetramer populations.

(B) Tetramer CD4⁺ and CD8⁺ T cell frequencies of healthy (n = 16, ChAdOx1 = 4, BNT162b2 = 12) and hematology groups (n = 54, ChAdOx1 = 35, BNT162b2 = 19) per vaccine type. Any samples with <10 tetramer⁺ events are shown as open symbols. 1–3 tetramer responses shown per donor.

(C) r_s of T1 tetramer frequencies versus T5 or T7/T8.

(D) r_s of tetramer frequencies versus B cell numbers at T5.

(E–G) Tetramer frequencies per (E) epitope, (F) malignancy and immunosuppressive treatment, or (G) at T5 where median and IQR are shown.

(H) Phenotype frequencies of tetramer⁺ cells from healthy (gray line) and hematology patients (orange line).

(I) Tetramer⁺ phenotype per malignancy and immunosuppressive treatment.

The frequency of tetramer⁺ cells are right shifted by 10⁻⁷ (i.e., no detected tetramer⁺ events displayed as 10⁻⁷). Only samples with 10 or more tetramer⁺ events are included for (H) and (I). Statistical significance determined by Wilcoxon test for time point comparisons against T1 (floating values); Mann-Whitney for comparisons between healthy and patient timepoints (connecting line); (G) Dunn’s multiple comparisons set on healthy versus all other disease groups; and (H) Sidak’s multiple comparison test and (I) Dunnett’s multiple comparison test for time point comparisons against T1. ∗∗∗∗p < 0.0001. Experiments were performed once for each sample. Refer to Figures S2E and S7.